Clostridium difficile Biofilm
Clostridium difficile infection (CDI) is an important healthcare-associated disease worldwide, mainly occurring after antimicrobial therapy. Antibiotics administered to treat a number of infections can promote C. difficile colonization of the gastrointestinal tract and, thus, CDI. A rise in multidrug resistant clinical isolates to multiple antibiotics and their reduced susceptibility to the most commonly used antibiotic molecules have made the treatment of CDI more complicated, allowing the persistence of C. difficile in the intestinal environment.
Gut colonization and biofilm formation have been suggested to contribute to the pathogenesis and persistence of C. difficile. In fact, biofilm growth is considered as a serious threat because of the related increase in bacterial resistance that makes antibiotic therapy often ineffective. However, although the involvement of the C. difficile biofilm in the pathogenesis and recurrence of CDI is attracting more and more interest, the mechanisms underlying biofilm formation of C. difficile as well as the role of biofilm in CDI have not been extensively described.
Findings on C. difficile biofilm, possible implications in CDI pathogenesis and treatment, efficacy of currently available antibiotics in treating biofilm-forming C. difficile strains, and some antimicrobial alternatives under investigation will be discussed here.
KeywordsBiofilm Clostridium difficile Genetic factors EPS matrix Adhesion
- Borriello SP (1979) Clostridium difficile and its toxin in the gastrointestinal tract in health and disease. Res Clin Forums 1:33–35Google Scholar
- Hashem AA, Abd El Fadeal NM et al (2017) In vitro activities of vancomycin and linezolid against biofilm-producing methicillin-resistant staphylococci species isolated from catheter-related bloodstream infections from an Egyptian tertiary hospital. J Med Microbiol 66:744–752PubMedCrossRefGoogle Scholar
- Machado D, Castro J, Palmeira-de-Oliveira A et al (2015) Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol 6:152Google Scholar
- Normington C, Chilton C, Buckley A, et al (2017) Influence of gut microflora on C. difficile biofilm formation. In: Microbiology society annual conference, p P418Google Scholar
- Piotrowski M, Karpiński P, Pituch H, van Belkum A, Obuch-Woszczatyński P (2017) Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-017-2980-1
- Rossi E, Cimdins A, Lüthje P et al (2017) “It’s a gut feeling” – Escherichia coli biofilm formation in the gastrointestinal tract environment. Crit Rev Microbiol 9:1–30Google Scholar
- Roy R, Tiwari M, Donelli G et al (2017) Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. https://doi.org/10.1080/21505594.2017.1313372
- Slater, Unnkrishnan M (2015) Characterisation of LuxS dependent biofilm formation by Clostridium difficile. In: 5th international Clostridium difficile symposium, p P76Google Scholar
- Soavelomandroso AP, Bouttier S, Hoys S, Candela T, Janoir C (2015). Spatial organization of tissue-associated bacteria in a Clostridium difficile monoxenic mouse model.P95, 5th International Clostridium difficile Symposium. Bled, SloveniaGoogle Scholar
- Swidsinski A, Mendling W, Loening-Baucke V et al (2008) An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 198(97):e1–e6Google Scholar
- Walter BM, Cartman ST, Minton NP et al (2015) The SOS response master regulator LexA is associated with sporulation, motility and biofilm formation in Clostridium difficile. PLoS One 10:1–17Google Scholar